Baird served as a co-manager on this transaction
AboutSynageva BioPharma Corp. (“Synageva” or the “Company”) (NASDAQ-GS: GEVA) recently completed a follow-on offering of 2,000,000 shares of common stock at a price of $105.75 per share, generating gross proceeds of $211.5 million. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include expanding their infrastructure, including commercial and manufacturing, to benefit sebelipase alfa and the rest of their pipeline, supporting the advancement of SBC- 103 and accelerating their early- stage programs into the clinic and leveraging their proprietary platform technology to initiate and accelerate multiple new pipeline programs to expand beyond the current opportunity set.
Synageva is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The company’s most advanced pipeline programs are enzyme replacement therapies for lysosomal storage diseases (LSDs) and it has additional protein therapeutic programs for other rare diseases, which are currently at different stages of preclinical development. Synageva’s lead program, sebelipase alfa for lysosomal acid lipase deficiency (LAL Deficiency), is in global Phase 3 clinical trials. Synageva is headquartered in Lexington, Massachusetts.
For additional information about this transaction, please contact:
- March 2014
- Synageva BioPharma Corp.
- Target Location
- North America